Login to Your Account

Celgene, Vertex report earnings, too
Rare disease specialist Alexion Pharmaceuticals Inc. is striding ahead with fast-rising sales of its sole approved product, Soliris (eculizumab), and soon a new chief executive, it said in an earnings report Thursday. more »

Our Habitat for All Things Science
Genome studies broaden and deepen as methods progress

TOKYO – In the nearly 12 years since the completion of the Human Genome Project, next-generation sequencing methods have made genome sequencing both faster and cheaper, leading to massive increases in the numbers of individuals who can be sequenced. Projects have gone from the Human Genome Project, to the 1,000 Genomes Project, to the announcement last week of a 100,000 Genomes Project that plans to start recruiting patients in February 2015. (See BioWorld Today, Dec. 23, 2014.)